Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Security

Ventyx Biosciences Inc. Common Stock · VTYX

VTYXNASDAQCommon stockHistorical · closed Mar 4, 2026CIK 1851194Updated Oct 6, 2026

Company: Ventyx Biosciences, Inc. →

VTYX price & chart

Provider market data
Historical security

This listing closed Mar 4, 2026. Live provider charts are shown only for current listings.

About the company

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with inflammation-mediated diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated oral small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drug candidates through clinical trials. Our portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor that demonstrated significant reductions in cardiovascular risk factors in a recently reported Phase 2 trial. In addition, VTX3232 recently completed a Phase 2 biomarker study in early-stage Parkinson’s disease. Our broader inflammatory bowel disease portfolio includes two Phase 2 compounds: tamuzimod (VTX002), a S1P1R modulator and VTX958, a TYK2 inhibitor.

DEFA14A · 2026-01-07 · 0001193125-26-006527

Company description from the cited filing.

Financials

FY 2024 · USD
Revenue— · FY 2024
Net income-135,122,000USD · FY 2024
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

Operating income-148,450,000USD · FY 2024
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

Diluted EPS-1.97USD per share · FY 2024
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

Some figures are unavailable for this reporting year.

balance sheet · annual statements
Line itemQ3 2025Q3 2024Q3 2023Q2 2025Q2 2024Q2 2023Q1 2025Q1 2024FY 2024FY 2023FY 2022FY 2021
ASSETS
AssetsUSD211,465,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

301,100,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

321,701,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

230,009,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

309,193,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

348,763,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

253,480,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

332,078,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

276,563,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

277,693,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

371,400,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

291,482,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Property, Plant and Equipment, NetUSD501,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

703,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

686,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

549,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

762,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

629,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

522,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

828,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

614,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

762,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

407,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

254,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Current assets:
Cash and Cash Equivalents, at Carrying ValueUSD31,970,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

61,765,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2024-09-30

56,610,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2023-09-30

32,301,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

40,925,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2024-06-30

51,717,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2023-06-30

28,076,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

141,898,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2024-03-31

27,260,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

51,579,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

64,819,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

70,791,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Assets, CurrentUSD201,094,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

289,408,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

308,092,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

219,322,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

256,931,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

346,701,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

242,558,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

319,759,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

229,625,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

264,345,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

330,688,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

263,020,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Operating Lease, Right-of-Use AssetUSD8,883,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

9,918,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

11,846,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

9,151,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

10,162,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

1,331,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

9,413,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

10,414,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

9,669,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

11,509,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

1,537,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

—
Other Assets, NoncurrentUSD12,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

96,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

102,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

12,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

102,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

102,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

12,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

102,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

59,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

102,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

96,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

60,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

LIABILITIES AND EQUITY
LiabilitiesUSD20,101,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

22,328,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

38,061,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

20,626,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

28,398,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

20,956,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

21,847,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

25,082,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

22,518,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

33,770,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

17,505,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

12,283,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Stockholders’ equity:
Common Stock, Value, IssuedUSD7,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

7,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

6,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

7,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

7,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

6,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

7,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

7,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

7,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

6,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

6,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

5,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Additional Paid in CapitalUSD822,699,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

802,850,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

656,575,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

817,864,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

770,745,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

646,918,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

813,221,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

764,869,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

808,190,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

663,154,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

581,237,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

397,051,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Retained Earnings (Accumulated Deficit)USD-631,565,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

-524,958,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

-372,434,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

-608,736,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

-489,709,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

-318,407,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

-581,749,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

-457,759,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

-554,309,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

-419,187,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

-226,225,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

-117,799,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Accumulated Other Comprehensive Income (Loss), Net of TaxUSD223,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

873,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

-507,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

248,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

-248,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

-710,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

154,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

-121,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

157,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

-50,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

-1,123,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

-58,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Stockholders' Equity Attributable to ParentUSD191,364,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

278,772,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2024-09-30

283,640,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2023-09-30

209,383,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

280,795,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2024-06-30

327,807,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2023-06-30

231,633,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

306,996,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2024-03-31

254,045,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

243,923,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

353,895,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

279,199,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Liabilities and EquityUSD211,465,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

301,100,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

321,701,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

230,009,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

309,193,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

348,763,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

253,480,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

332,078,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

276,563,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

277,693,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

371,400,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

291,482,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Current liabilities:
Liabilities, CurrentUSD11,259,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

12,303,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

26,208,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

11,469,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

18,104,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

20,034,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

12,394,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

14,534,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

12,776,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

22,265,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

16,359,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

12,283,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Operating Lease, Liability, CurrentUSD1,182,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

1,011,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

479,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

1,138,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

971,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

439,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

1,094,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

946,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

1,052,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

1,001,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

412,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

—
Accounts Payable, CurrentUSD993,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

2,286,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

9,338,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

913,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

6,583,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

4,085,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

2,320,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

5,583,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

3,130,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

5,756,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

6,433,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

4,661,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Operating Lease, Liability, NoncurrentUSD8,842,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

10,025,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

11,853,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

9,157,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

10,294,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

922,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

9,453,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

10,548,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

9,742,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

11,505,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

1,146,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

—
Additional Financial Items
Accrued Liabilities, CurrentUSD9,084,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

9,006,000
Source

10-Q · 2024-11-07 · 0000950170-24-123485

As of 2024-09-30

16,391,000
Source

10-Q · 2023-11-09 · 0000950170-23-062098

As of 2023-09-30

9,418,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

10,550,000
Source

10-Q · 2024-08-08 · 0000950170-24-094007

As of 2024-06-30

15,510,000
Source

10-Q · 2023-08-10 · 0000950170-23-041347

As of 2023-06-30

8,980,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

8,005,000
Source

10-Q · 2024-05-09 · 0000950170-24-057003

As of 2024-03-31

8,594,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

15,508,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

9,514,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

7,622,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Cash, Cash Equivalents, and Short-term InvestmentsUSD————————252,900,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

252,200,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

356,600,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

286,700,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

Lines labelled “Derived” are calculated from reported figures.

cash flow · annual statements
Line itemQ4 2024Q4 2023Q3 2025Q3 2024Q2 2025Q2 2024Q1 2025Q1 2024FY 2024FY 2023FY 2022FY 2021
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD——————-27,440,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

-38,572,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

-135,122,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

-192,962,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

-108,426,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

-83,746,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Adjustments to reconcile net income to net cash provided by operating activities:
Share-based Payment Arrangement, Noncash ExpenseUSD——————5,031,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

6,543,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

22,931,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

28,588,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

16,570,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

2,730,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Changes in operating assets and liabilities:
Increase (Decrease) in Accounts PayableUSD——————-809,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

-1,190,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

-2,644,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

-745,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

1,613,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

2,443,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Net Cash Provided by (Used in) Operating ActivitiesUSD——————-25,718,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

-47,625,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

-130,873,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

-166,522,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

-98,771,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

-38,650,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Cash flows from investing activities:
Payments to Acquire Businesses, Net of Cash AcquiredUSD———————————-1,899,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Net Cash Provided by (Used in) Investing ActivitiesUSD——————26,415,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

41,765,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

-15,506,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

100,940,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

-74,931,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

-214,365,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Payments to Acquire Property, Plant, and EquipmentUSD——————16,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

175,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

241,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

514,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

275,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

262,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Cash flows from financing activities:
Net Cash Provided by (Used in) Financing ActivitiesUSD———————96,184,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

122,115,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

53,329,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

167,772,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

323,551,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD——————816,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

90,319,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

-24,319,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

-12,265,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

-5,972,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

70,547,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD——32,945,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2025-09-30

62,740,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

As of 2024-09-30

33,276,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2025-06-30

41,900,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

As of 2024-06-30

29,051,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2025-03-31

142,873,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

As of 2024-03-31

28,235,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

52,554,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

——
Supplemental disclosure of cash flow information:
Income Taxes Paid, NetUSD———————————3,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Additional Financial Items
Share-based Payment Arrangement, ExpenseUSD——4,601,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

5,451,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

4,575,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

5,771,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

5,031,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

6,543,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

22,931,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

28,588,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

16,570,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

2,730,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Cash, Cash Equivalents, and Short-term InvestmentsUSD————————252,900,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

As of 2024-12-31

252,200,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

As of 2023-12-31

356,600,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

As of 2022-12-31

286,700,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

As of 2021-12-31

DepreciationUSD——100,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

100,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

100,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

100,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

100,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

70,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

266,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

158,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

123,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

30,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Gain (Loss) on Disposition of Property Plant EquipmentUSD———————-98,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

-136,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

———
Gain (Loss) on Termination of LeaseUSD———————88,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

88,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

———
General and Administrative ExpenseUSD——7,168,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

7,923,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

7,067,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

7,907,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

7,199,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

8,021,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

31,448,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

32,227,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

25,398,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

8,666,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Investment Income, InterestUSD——2,055,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

3,350,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

2,367,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

3,783,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

2,666,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

3,227,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

13,416,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

15,074,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

4,669,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

—
Net Income (Loss) Attributable to ParentUSD——-22,829,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

-35,249,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

-26,987,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

-31,950,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

-27,440,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

-38,572,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

-135,122,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

-192,962,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

-108,426,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

-83,746,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Net Income (Loss) Available to Common Stockholders, BasicUSD——————————-108,426,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

-85,298,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Nonoperating Income (Expense)USD——2,045,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

3,303,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

2,346,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

3,762,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

2,657,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

3,196,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

13,328,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

15,032,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

4,710,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

-16,599,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Operating ExpensesUSD——24,874,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

38,552,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

29,333,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

35,712,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

30,097,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

41,768,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

148,450,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

207,994,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

113,136,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

67,147,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Other Nonoperating Income (Expense)USD——-10,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

-47,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

-21,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

-21,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

-9,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

-31,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

-88,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

-42,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

41,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

27,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Proceeds from Stock Options ExercisedUSD———————92,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

261,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

4,671,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

2,107,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

65,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemQ4 2024Q4 2023Q3 2025Q3 2024Q2 2025Q2 2024Q1 2025Q1 2024FY 2024FY 2023FY 2022FY 2021
Operating Income (Loss)USD——-24,874,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

-38,552,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

-29,333,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

-35,712,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

-30,097,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

-41,768,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

-148,450,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

-207,994,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

-113,136,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

-67,147,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Other Nonoperating Income (Expense)USD——-10,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

-47,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

-21,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

-21,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

-9,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

-31,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

-88,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

-42,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

41,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

27,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD————————-135,086,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

-192,931,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

——
Net Income (Loss) Attributable to ParentUSD——-22,829,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

-35,249,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

-26,987,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

-31,950,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

-27,440,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

-38,572,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

-135,122,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

-192,962,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

-108,426,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

-83,746,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Earnings Per Share, BasicUSD per share——-0.32
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

-0.5
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

-0.38
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

-0.45
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

-0.39
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

-0.62
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

-1.97
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

-3.3
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

-2.07
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

—
Earnings Per Share, DilutedUSD per share——-0.32
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

-0.5
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

-0.38
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

-0.45
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

-0.39
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

-0.62
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

-1.97
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

-3.3
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

-2.07
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

—
Weighted Average Number of Shares Outstanding, Basicshares——71,304,084
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

70,667,570
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

71,198,652
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

70,554,718
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

71,131,439
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

61,829,976
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

68,478,172
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

58,542,974
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

52,471,003
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

—
Weighted Average Number of Shares Outstanding, Dilutedshares——71,304,084
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

70,667,570
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

71,198,652
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

70,554,718
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

71,131,439
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

61,829,976
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

68,478,172
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

58,542,974
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

52,471,003
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

—
Additional Financial Items
General and Administrative ExpenseUSD——7,168,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

7,923,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

7,067,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

7,907,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

7,199,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

8,021,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

31,448,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

32,227,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

25,398,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

8,666,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD————————-40,775,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

-121,383,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

-52,073,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

—
Investment Income, InterestUSD——2,055,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

3,350,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

2,367,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

3,783,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

2,666,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

3,227,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

13,416,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

15,074,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

4,669,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

—
Net Income (Loss) Available to Common Stockholders, BasicUSD——————————-108,426,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

-85,298,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Nonoperating Income (Expense)USD——2,045,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

3,303,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

2,346,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

3,762,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

2,657,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

3,196,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

13,328,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

15,032,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

4,710,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

-16,599,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Operating ExpensesUSD——24,874,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

38,552,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

29,333,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

35,712,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

30,097,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

41,768,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

148,450,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

207,994,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

113,136,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

67,147,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Preferred Stock Dividends, Income Statement ImpactUSD———————————1,552,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Research and Development ExpenseUSD——17,706,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2025-07-01 to 2025-09-30

30,629,000
Source

10-Q · 2025-11-06 · 0001193125-25-269517

2024-07-01 to 2024-09-30

22,266,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2025-04-01 to 2025-06-30

27,805,000
Source

10-Q · 2025-08-07 · 0001851194-25-000009

2024-04-01 to 2024-06-30

22,898,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2025-01-01 to 2025-03-31

33,747,000
Source

10-Q · 2025-05-08 · 0000950170-25-066996

2024-01-01 to 2024-03-31

117,002,000
Source

10-K · 2025-02-27 · 0000950170-25-029245

2024-01-01 to 2024-12-31

175,767,000
Source

10-K · 2024-02-27 · 0000950170-24-021160

2023-01-01 to 2023-12-31

87,738,000
Source

10-K · 2023-03-23 · 0000950170-23-009501

2022-01-01 to 2022-12-31

58,481,000
Source

10-K · 2022-03-24 · 0000950170-22-004442

2021-01-01 to 2021-12-31

Lines labelled “Derived” are calculated from reported figures.

Offerings

Registration 333-278584

POS AM · 2026-03-04 · 0001193125-26-090533

Terms from the governing filing for this registration; not a claim that the offering is open today.

Registration 333-283076

POS AM · 2026-03-04 · 0001193125-26-090536

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

ex99_1.htm · SCHEDULE 13G/A · 2026-05-15

Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.0001 per share, of Ventyx Biosciences, Inc. and further agree to the filing of this agreement as an exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agr…

SCHEDULE 13G/A · 2026-05-15 · 0001214659-26-006497

Read attachment ↗
d98679dex991.htm · 8-K · 2026-01-07

Exhibit 99.1 Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases Ventyx’s clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly’s established capabilities in inflammatory-mediated diseases INDIANAPOLIS, Jan. 7, 2026 /PRNewswire/ - Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmac…

8-K · 2026-01-07 · 0001193125-26-006520

Read attachment ↗
vtyx-ex99_1.htm · 8-K · 2025-11-06

EX-99.1 2 vtyx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress • Data from the recent Phase 2 study position Ventyx’s NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease • Positive topline data from Phase 2a biomarker trial support the potential use of VTX3232 as a disease-modifying therapy for patients with Parkinson’s disease • Topline d…

8-K · 2025-11-06 · 0001193125-25-269459

Read attachment ↗
d98315dex991.htm · 8-K · 2025-10-22

EX-99.1 2 d98315dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first week VTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for c…

8-K · 2025-10-22 · 0001193125-25-246808

Read attachment ↗
d98315dex992.htm · 8-K · 2025-10-22

EX-99.2 3 d98315dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Phase 2 Trial of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors Topline Results October 22, 2025 Forward Looking Statements Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking …

8-K · 2025-10-22 · 0001193125-25-246808

Read attachment ↗
vtyx-ex99_1.htm · 8-K · 2025-08-07

EX-99.1 2 vtyx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress • Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson’s disease • Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025 • Phase 2 study of VTX3232 in participants with obesity and cardiometabolic risk factors i…

8-K · 2025-08-07 · 0001851194-25-000007

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.